Nuvation Bio (NUVB) Change in Receivables (2024 - 2026)
Nuvation Bio (NUVB) posted quarterly Change in Receivables of $6.6 million for Q1 2026, up 153.98% year-over-year from $2.6 million in Q1 2025, and down 14.27% quarter-over-quarter from $7.8 million in Q4 2025.
Nuvation Bio (NUVB) Change in Receivables (2024 - 2026) Analysis & Trends
Nuvation Bio (NUVB) has reported Change in Receivables for 3 consecutive years, with $6.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Receivables rose 153.98% year-over-year to $6.6 million; the TTM figure through Mar 2026 stood at $22.3 million (up 5355.75% YoY), while the FY2025 annual figure was $3.4 million, down 73.64% from the prior year.
- Change in Receivables declined to $6.6 million in Q1 2026 per NUVB's latest filing, from $7.8 million in the prior quarter.
- Across five years, Change in Receivables topped out at $12.6 million in Q4 2024 and bottomed at -$12.3 million in Q1 2025.
- Historically, Change in Receivables has averaged $2.8 million across 3 years, with a median of $4.0 million in 2025.
- On a YoY basis, Change in Receivables climbed as much as 112700.0% in 2025 and fell as far as 38.52% in 2025.
- Nuvation Bio's Change in Receivables stood at $12.6 million in 2024, then tumbled by 38.52% to $7.8 million in 2025, then slipped by 14.27% to $6.6 million in 2026.
- Business Quant data shows NUVB's Change in Receivables at $6.6 million in Q1 2026, $7.8 million in Q4 2025, and $5.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Nuvation Bio | 2.16 Bn | 2.16 Bn | 30.78 Mn | 5.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.10 Mn |
| Jun 30, 2026 | 5.10 Mn |
| Mar 31, 2026 | 6.65 Mn |
| Mar 31, 2026 | 6.65 Mn |
| Dec 31, 2025 | 7.75 Mn |
| Dec 31, 2025 | 7.75 Mn |
| Sep 30, 2025 | 5.63 Mn |
| Sep 30, 2025 | 5.63 Mn |
| Jun 30, 2025 | 2.28 Mn |
| Jun 30, 2025 | 2.28 Mn |
| Mar 31, 2025 | -12.31 Mn |
| Mar 31, 2025 | -12.31 Mn |
| Dec 31, 2024 | 12.61 Mn |
| Dec 31, 2024 | 12.61 Mn |
| Sep 30, 2024 | -5,000.00 |
| Sep 30, 2024 | -5,000.00 |
| Jun 30, 2024 | 117,000.00 |
| Jun 30, 2024 | 117,000.00 |